<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099903</url>
  </required_header>
  <id_info>
    <org_study_id>18400613.1.0000.0068</org_study_id>
    <nct_id>NCT02099903</nct_id>
  </id_info>
  <brief_title>Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease</brief_title>
  <official_title>Transcatheter Renal Denervation in Patients With Systolic Heart Failure Due to Chagas' Disease - a Safety and Efficacy Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>InCor Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a randomized prospective controlled study of transcatheter renal denervation in&#xD;
      patients with systolic heart failure secondary to Chagas' disease. The purpose of the study&#xD;
      is to evaluate the safety and effectiveness of renal denervation in patients with Chagas&#xD;
      heart disease, due to reduction in renal and systemic sympathetic activity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The activation of the sympathetic nervous system is one of the main mechanisms involved in&#xD;
      heart failure pathophysiology, as well as activation of the renin-angiotensin-aldosterone&#xD;
      system. These compensatory mechanisms are initially beneficial, in order to restore adequate&#xD;
      cardiac output. Their long-term activation, nevertheless, leads to several deleterious&#xD;
      effects on cardiovascular system, such as direct myocite lesion, cardiac hypertrophy,&#xD;
      myocardial ischemia, oxidative stress, cardiac arrhythmias and myocite apoptosis, among&#xD;
      others.&#xD;
&#xD;
      It has been widely demonstrated that modulation of sympathetic nervous system is an important&#xD;
      therapeutic target for the treatment of systolic heart failure. Beta-blocker and ACE&#xD;
      inhibitors therapies are the main stem of heart failure treatment and have demonstrated&#xD;
      reduction in morbidity and mortality of this condition. Despite optimized medical treatment,&#xD;
      heart failure carries a poor prognosis.&#xD;
&#xD;
      Surgical sympathectomy has been used decades ago for the treatment of malignant hypertension&#xD;
      and showed marked reduction in arterial pressure. However, these procedures were very&#xD;
      aggressive and lead to long hospitalization and recovery periods, as well as several limiting&#xD;
      adverse effects. Recently, transcatheter renal denervation has evolved as a promising and&#xD;
      less invasive technique, which allows destruction of renal nerves located on the adventitia&#xD;
      of the renal arteries. The ablation procedure is performed by delivery of radiofrequency&#xD;
      energy from the tip of a catheter positioned into the renal arteries, through standard&#xD;
      femoral artery catheterization, a less morbid and safer approach.&#xD;
&#xD;
      Renal denervation has been tested mainly in patients with resistant hypertension, among other&#xD;
      indications, with promising results. The pathophysiological basis for this treatment in&#xD;
      hypertension, as well as heart failure, stands on the participation of renal afferent and&#xD;
      efferent nerves on the maintenance of elevated systemic vascular resistance. Activation of&#xD;
      efferent nerves leads to excretion o renin, aldosterone, angiotensin II, elevated&#xD;
      norepinephrine levels and consequent retention of salt and water and reduction of renal blood&#xD;
      flow. This mechanism and also afferent renal nerves activation contributes to the elevation&#xD;
      of sympathetic tonus on the central nervous system.&#xD;
&#xD;
      In animal models of heart failure, renal denervation demonstrated improvement on renal and&#xD;
      cardiac function. Initial clinical studies suggest that this intervention is safe and&#xD;
      potentially effective on the treatment of heart failure in humans. Chagas heart disease is a&#xD;
      prevalent cause of heart failure in Brazil and shares several pathophysiological aspects&#xD;
      described for other causes of heart failure. Our aim is to evaluate the safety and&#xD;
      effectiveness of renal denervation in systolic heart failure due to Chagas Heart disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite: death, myocardial infarction, cerebrovascular event, need of intervention on renal arteries and renal function impairment (decrease in estimated GFR &gt; 30% from baseline).</measure>
    <time_frame>30 days.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF) by echocardiography.</measure>
    <time_frame>9 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional class.</measure>
    <time_frame>9 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test</measure>
    <time_frame>9 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Oxygen consumption (VO2) by ergoespirometry.</measure>
    <time_frame>9 months.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in serum B-type natriuretic peptide (BNP).</measure>
    <time_frame>9 months.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life assessed by Minnesota and EuroQOL five dimensions (EQ-5D)questionnaires.</measure>
    <time_frame>9 months.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral sympathetic activity measured by microneurography.</measure>
    <time_frame>9 months.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <condition>Heart Failure, Systolic</condition>
  <condition>Chagas Disease</condition>
  <condition>Chagas Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Medical therapy for heart failure</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard optimized medical therapy for heart failure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal denervation + medical therapy.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter Renal Denervation with irrigated radiofrequency catheter + standard medical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcatheter renal denervation</intervention_name>
    <description>Renal sympathetic denervation with an irrigated radiofrequency catheter.</description>
    <arm_group_label>Renal denervation + medical therapy.</arm_group_label>
    <other_name>Celsius Thermocool (Biosense Webster, California, USA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥ 18 to ≤ 70 years of age with chronic systolic heart failure, Chagas disease&#xD;
             etiology.&#xD;
&#xD;
          2. Two positive serology results for Chagas by two distinct methods.&#xD;
&#xD;
          3. NYHA (New York Heart Association) class II or III.&#xD;
&#xD;
          4. Patients treated with maximum tolerated doses of standard pharmacotherapy for heart&#xD;
             failure.&#xD;
&#xD;
          5. LVEF (Left Ventricular Ejection Fraction) ≤ 40% (Simpson Method).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with NYHA class I or IV.&#xD;
&#xD;
          2. Sustained ventricular tachycardia (&gt;30 sec) or with hemodynamic compromise.&#xD;
&#xD;
          3. Presence of permanent pacemaker or implantable defibrillator.&#xD;
&#xD;
          4. Systolic blood pressure &lt; 90 mmHg.&#xD;
&#xD;
          5. Heart beat &lt; 60 bpm at rest.&#xD;
&#xD;
          6. Advanced renal insufficiency (estimated glomerular filtration rate (GFR) &lt; 30&#xD;
             ml/min/1.73 square meters).&#xD;
&#xD;
          7. Patients with planned cardiac surgery or percutaneous revascularization.&#xD;
&#xD;
          8. Other reasons which would preclude the patient from participating in the study&#xD;
             (comorbidities, life expectancy less than 1 year).&#xD;
&#xD;
          9. Unsuitable anatomy of renal arteries, renal stenosis or previous treatment with&#xD;
             balloon or stent.&#xD;
&#xD;
         10. Refusal of the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Heart Institute - InCor. University of Sao Paulo Medical School</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Pereira</last_name>
      <phone>+55 11 2661-5368</phone>
      <email>patricia.pereira@incor.usp.br</email>
    </contact>
    <investigator>
      <last_name>Pedro Lemos, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>InCor Heart Institute</investigator_affiliation>
    <investigator_full_name>Pedro A. Lemos</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Heart Failure, Systolic</keyword>
  <keyword>Chagas Disease</keyword>
  <keyword>Chagas Cardiomyopathy</keyword>
  <keyword>Renal Denervation</keyword>
  <keyword>Irrigated Radiofrequency Catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
    <mesh_term>Chagas Cardiomyopathy</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

